Leonhardt Ventures LLC today announced a major leap forward in regenerative medical technology with the introduction of E-Stent™, the first wireless, bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues.
Developed by the Leonhardt R&D engineering team in Irvine, led by CTO Brian Lasater and CEO Howard Leonhardt, the E-Stent™ system combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions (bioelectric signals) to micro-coils embedded along the stent. Stent sizes range from micro-implants smaller than a pea to 28 mm aortic stents, enabling applications across multiple organ systems.
"This is no longer a theory or a dream; we have working prototypes in testing now which are controlling regenerative and healing protein expressions on demand, enabled fully by wireless energy," stated Brian Lasater, CTO of Leonhardt Ventures LLC and Lionheart Health, Inc.
Leonhardt Ventures LLC has granted exclusive licenses for the E-Stent™ platform to several entities, including KidneyCell™ (kidney-cell.com) for kidney regeneration, CerebraCell™ (cerebracell.com) for brain health and stroke recovery, and CancerCell™ (cancercellinc.com) for cancer treatment, among others. Other licensed applications include memory improvement, addiction treatment, heart regeneration, vision and hearing restoration, and orthopedics.
Through selective bioelectric signaling, the E-Stent™ platform can stimulate or inhibit a broad range of proteins, including klotho, sestrins, sirtuins, apelin, and many others known to influence stem cell homing, proliferation, and differentiation. This can improve circulation, restore muscle strength, modulate inflammation and blood pressure, and improve nerve connections and viability.
This platform represents a significant evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant, expanding the same core capabilities into advanced vascular implant formats.
The Lionheart Health team was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025 (medicaltechoutlook.com/lionheart-health-inc). Lionheart Health was also recognized as Abbvie Allergan ULP Innovation of the Year in Medical Aesthetics and as a top 40 semi-finalist in the $101 Million Xprize Healthspan competition.
